Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome, GSK Agree on Possible Use of DNA Methylation Biomarker

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoMethylome Sciences today announced an agreement with GlaxoSmithKline Biologics for the potential use of a DNA methylation-specific biomarker for the development of immunotherapeutics.

The two firms began a collaboration in 2007, and today's agreement "marks an important step for our company in the use of our biomarker with certain immunotherapeutics in development by GSK," said Jan Groen, CEO of OncoMethylome. He added that it "underpins our strategy of leveraging our methylation-specific PCR platform" for the development of companion diagnostics and personalized medicine.

The biomarker, the Belgian company said, allows for the analysis of non-invasive tissue samples.

Financial terms of the agreement were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.